Biomaterial-mediated internal radioisotope therapy.

Abstract

Radiation therapy (RT), including external beam radiotherapy (EBRT) and internal radioisotope therapy (RIT), has been an indispensable strategy for cancer therapy in clinical practice in recent years. Ionized atoms and free radicals emitted from the nucleus of radioisotopes can cleave a single strand of DNA, inducing the apoptosis of cancer cells. Thus far, nuclides used for RIT could be classified into three main types containing alpha (α), beta (β), and Auger particle emitters. In order to enhance the bioavailability and reduce the physiological toxicity of radioisotopes, various biomaterials have been utilized as multifunctional nanocarriers, including targeting molecules, macromolecular monoclonal antibodies, peptides, inorganic nanomaterials, and organic and polymeric nanomaterials. Therapeutic radioisotopes have been labeled onto these nanocarriers via different methods (chelating, chemical doping, encapsulating, displacement) to inhibit or kill cancer cells. With the continuous development of research in this respect, more promising biomaterials as well as novel therapeutic strategies have emerged to achieve the high-performance RIT of cancer. In this review article, we summarize recent advances in biomaterial-mediated RIT of cancer and provide guidance for non-experts to understand nuclear medicine and to conduct cancer radiotherapy.

• Authors: Pei Pei, Teng Liu, Wenhao Shen, Zhuang Liu, Kai Yang
• Journal: Materials horizons (Mater Horiz) Vol. 8 Issue 5 Pg. 1348-1366 (05 01 2021) ISSN: 2051-6355 [Electronic] England
• PMID: 34846446 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Biocompatible Materials
• Radioisotopes
• Radiopharmaceuticals

Topics

• Antibodies, Monoclonal
• Biocompatible Materials
• Humans
• Neoplasms (radiotherapy)
• Radioimmunotherapy
• Radioisotopes
• Radiopharmaceuticals